Arvinas initiated with an Outperform at Evercore ISI. Evercore ISI analyst Ravi Mehrotra initiated Arvinas with an Outperform rating and a price targets of $24. The analyst sees the company as a “leading player in protein degradation” and the only one being at the clinical stage, offering a “high potential for scalability modularity”.
https://thefly.com/landingPageNews.php?id=2891661
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.